1071 related articles for article (PubMed ID: 21255197)
1. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
3. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
4. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Jenner P
Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
[TBL] [Abstract][Full Text] [Related]
5. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
7. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
Gottwald MD
Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
Stathis P; Konitsiotis S; Antonini A
Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
[TBL] [Abstract][Full Text] [Related]
10. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
11. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
13. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Damier P; Viallet F; Ziegler M; Bourdeix I; Rerat K
Eur J Neurol; 2008 Jul; 15(7):643-8. PubMed ID: 18582341
[TBL] [Abstract][Full Text] [Related]
14. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
15. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
16. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
17. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
[TBL] [Abstract][Full Text] [Related]
18. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
19. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
Olanow CW; Stocchi F
Neurology; 2004 Jan; 62(1 Suppl 1):S72-81. PubMed ID: 14718683
[TBL] [Abstract][Full Text] [Related]
20. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
